Kitano Shigehisa
Dept. of Experimental Therapeutics, National Cancer Center Hospital.
Gan To Kagaku Ryoho. 2017 Sep;44(9):727-732.
Recently, monotherapies of immune checkpoint inhibitor have been approved for some malignant tumors such as advanced melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin lymphoma, head and neck cancer in Japan. As the next step, to aim improvement of the clinical benefit, development of combination immunotherapies including immune checkpoint inhibitors are ongoing. In this chapter, recent strategies of clinical development of combination immunotherapy are described.
最近，免疫检查点抑制剂单药疗法已在日本被批准用于治疗某些恶性肿瘤，如晚期黑色素瘤、非小细胞肺癌、肾细胞癌、霍奇金淋巴瘤、头颈癌。下一步，为了提高临床获益，包括免疫检查点抑制剂在内的联合免疫疗法正在研发中。在本章中，将描述联合免疫疗法临床开发的最新策略。
